Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$239.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joshua Riggs
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 57
- Beta
- 1.86
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -23.89
Financials
Revenue
$239.0K+1393.8%Net Income
$-11.26MEBITDA
$-10.57MFree Cash Flow
$-10.05MEPS (diluted)
$-0.31Shares Outstanding (diluted)
36.75M+2667.3%Operating Expenses
$9.28MCash & Debt
$17.76MReturn of Capital
$0.00Revenue by Segment (annual)
$4.03MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.05M | $-50.22M | $-1.65 |
| 2024 | $1.88M | $-60.66M | $-4.66 |
| 2023 | $1.50M | $-27.78M | $-3.75 |
| 2022 | $958.0K | $-72.90M | $-20.00 |
| 2021 | $2.20M | $-64.10M | $-14.40 |
| 2020 | $1.22M | $-29.93M | $-9.14 |
| 2019 | $0.00 | $-22.33M | $-8.71 |
| 2018 | $0.00 | $-15.75M | $-8.32 |
| 2017 | $0.00 | $-19.38M | $-12.83 |
| 2016 | $0.00 | $-11.17M | $-8.42 |
| 2015 | $0.00 | $-8.73M | $-8.32 |
| 2014 | $0.00 | $-4.99M | $-4.58 |
| 2013 | $0.00 | $-3.50M | $-10.77 |
Valuation
IMDXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-62.50%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·2d ago·Neutral
…lization as First Patient Samples Arrive for GALACTIC Registry Study NASHVILLE, Tenn., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that the first several patients have been enrolled in its GALACTIC (GraftAssure Lowering Allograft rejeCTIon by Combination) registry study, a prospective, multi-center validation study evaluating GraftAssureTM, the company's molecular test for monitoring rejection in kidney transplant recipients.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Insight Molecular Diagnostics Inc. (IMDX) Q3 2026 Earnings Call Transcript Insight Molecular Diagnostics Inc. (IMDX) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·6d ago·Negative
What Oncocyte (IMDX) Said on Its Q3 Earnings Call Insight Molecular Diagnostics (IMDX) expects to respond before a January 2027 deadline to the U.S. Food and Drug Administration's request for more information about its GraftAssureDx kidney transplant test, executives said on the company's third-quarter earnings call.
View source ↗ - Newsglobenewswire.com·6d ago·Neutral
IMDx Reports Third Quarter 2026 Results and Provides Corporate Update NASHVILLE, Tenn., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its third quarter results:
View source ↗ - Newsglobenewswire.com·6d ago·Negative
Insight Molecular Diagnostics Announces Proposed Public Offering NASHVILLE, Tenn., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,” “us,” “our,” or the “Company”) today announced that it has commenced an underwritten public offering of shares of its common stock, or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, the Company intends to grant the underwriter a 30-day option to…
View source ↗ - Newsseekingalpha.com·97d ago·Positive
Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods Transcript Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods Transcript
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Thu, Apr 1(in 4 months)
Consensus estimate $-0.23 per share
Typical surprise -26.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.31 vs $-0.25miss
- Wed, May 13$-0.12 vs $-0.26beat
- Thu, Mar 26$-0.72 vs $-0.24miss
- Mon, Nov 10$-0.34 vs $-0.21miss
- Thu, Aug 14$-0.30 vs $-0.23miss
- Mon, May 12$-0.26 vs $-0.24miss
Estimates and results for IMDX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IMDX officers and directors.
- Bought
- $38.4m
- Sold
- —
29 trades
0 trades
- Broadwood Partners, L.p.bought
- Broadwood Partners, L.p.bought
- Broadwood Partners, L.p.bought
- Broadwood Partners, L.p.bought
- Broadwood Partners, L.p.bought
- Broadwood Partners, L.p.bought
- Broadwood Partners, L.p.bought
- James Andrea S.bought
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IMDX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
